Time filter

Source Type

The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species

The present invention relates to a fish protein hydrolysate having a biological activity of interest, in particular an effect on the stimulation and maintenance of bone. The fish protein hydrolysate is characterized in that it is obtained by enzymatic hydrolysis of at least one protein source selected from the fish species

Zair Y.,Institut Universitaire de France | Duclos E.,Compagnie des Peches Saint Malo Sante | Housez B.,Biofortis | Vergara C.,Clinical Trials Unit | And 2 more authors.
Nutrition and Food Science | Year: 2014

Purpose – This paper aims to investigate the satiety properties of a fish protein hydrolysate (blue whiting muscle hydrolysate, BWMH). Protein consumption is associated with higher satiety, protein being considered as the more satiating macronutrient. This property is extensively investigated in regard to weight management.Design/methodology/approach – Fifteen overweight women were included in a crossover design study. Subjects consumed 1 g of BWMH or placebo twice daily and sensations associated with satiety were recorded every day.Findings – Significant differences, in favour of BWMH, were highlighted on the desire to eat something sweet at T90 min (p < 0.05) and on plasma glucose at T270 min (p < 0.05).Research limitations/implications – This study demonstrates effect of BWMH on appetite. Indeed promising data were reported in favour of the test product, in particular on the desire to eat something sweet and on glucose levels. Some additional investigations will be necessary to support these data and those observed in in vitro and in vivo models. © Emerald Group Publishing Limited.

Cudennec B.,ProBioGEM | Fouchereau-Peron M.,French National Center for Scientific Research | Ferry F.,Compagnie des Peches Saint Malo Sante | Duclos E.,Compagnie des Peches Saint Malo Sante | Ravallec R.,ProBioGEM
Journal of Functional Foods | Year: 2012

To find appetite suppressive molecules derived from fish protein hydrolysates, both in vitro and in vivo experiments were performed in order to demonstrate that hydrolysates produced from blue whiting muscle (BWMH) possess satiating properties. Here we demonstrated for the first time that a protein hydrolysate obtained from marine source was able to enhance cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) secretion in STC-1 cell line. To demonstrate that these in vitro activities also exist in vivo, we investigated the effect of BWMH preload administration in rats and its repercussion on food intake and metabolic plasma marker levels. Results showed that BWMH reduced the short term food intake which was correlated to an increase in the CCK and GLP-1 plasma levels. Moreover it was demonstrated that the chronic administration of BWMH led to a decrease in the body weight gain. © 2011 Elsevier Ltd.

Nobile V.,SRL Group | Duclos E.,Compagnie des Peches Saint Malo Sante | Michelotti A.,SRL Group | Bizzaro G.,SRL Group | And 2 more authors.
Food and Nutrition Research | Year: 2016

Background: Fish protein hydrolysates (FPHs) have been reported as a suitable source of proteins for human nutrition because of their balanced amino acid composition and positive effect on gastrointestinal absorption. Objective: Here, we investigated the effect of a FPH, Slimpro®, obtained from blue whiting (Micromesistius poutassou) muscle by enzymatic hydrolysis, on body composition and on stimulating cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) secretion. Design: A randomized clinical study was carried out on 120, slightly overweight (25 kg/m2 5BMIB30 kg/m2), male (25%) and female (75%) subjects. FPH was tested in a food supplement at two doses (1.4 and 2.8 g) to establish if a dose-effect relationship exists. Product usewas associatedwith amild hypocaloric diet (300 kcal/day). Body composition (body weight; fat mass; extracellular water; and circumference of waist, thighs, and hips) and CCK/GLP-1 blood levels were measured at the beginning of the study and after 45 and 90 days of product use. CCK/GLP-1 levels were measured since they are involved in controlling food intake. Results: Treated subjects reported an improvement of body weight composition and an increased blood concentration of both CCK and GLP-1. No differences were found between the 1.4 and 2.8 g FPH doses, indicating a plateau effect starting from 1.4 g FPH. Conclusions: Both 1.4 and 2.8 g of FPH were effective in improving body composition and in increasing CCK and GLP-1 blood levels. © 2016 Vincenzo Nobile et al.

Discover hidden collaborations